Tezspire

Add-on maintenance treatment for inadequately controlled severe asthma despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment, in adult & adolescent ≥12 yr.

SC Adult & adolescent ≥12 yr 210 mg every 4 wk.

Hypersensitivity.

Hypersensitivity reactions (eg, anaphylaxis, rash) may occur following administration. Immediately discontinue in case of serious hypersensitivity reaction (eg, anaphylaxis). Discontinue therapy in case of serious infection &/or serious cardiac event while receiving treatment; if the patient becomes infected while receiving treatment & does not respond to anti-helminth treatment. Do not inj into areas where skin is tender, bruised, erythematous, or hardened. Not to be used to treat acute asthma exacerbations. Asthma-related symptoms or exacerbations may occur during treatment. Advise patients to seek medical advice if their asthma remains uncontrolled or worsens after treatment initiation. Abrupt corticosteroid discontinuation after initiation of therapy is not recommended; reduce dose gradually, if appropriate. Treat pre-existing serious infections &/or pre-existing helminth infections prior to tezepelumab treatment initiation. Serious cardiac adverse events may occur. Preferable to avoid use during pregnancy unless expected benefit to pregnant mother is greater than any possible risk to foetus. Risk to breast-fed child cannot be excluded during the 1st few days after birth. Safety & efficacy in childn <12 yr have not been established.

Pharyngitis; rash; arthralgia; inj site reaction.

Avoid use of live attenuated vaccines.

Other Drugs Acting on the Respiratory System

R03DX11 - tezepelumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.

K